Table 22.2 Partial list of humanized MAbs approved for therapeutic applications in humans

Product

Trade name

Indication

Target

Company (FDA

approval)

Necitumumab

Daclizumab

Transplantation

rejection

CD25

(a chain of

IL-2

receptor)

Roche (1997)

Palivizumab

Synagis^®

Respiratory syncytial

virus (RSV)

Fusion

protein of

RSV

MedImmune,

Abbott (1998)

Trastuzumab

Herceptin^®

Breast cancer,

metastatic gastric or

gastroesophageal

junction

adenocarcinoma

HER2

Genentech

(Roche) (1998)

Alemtuzumab

Campath^®

B cell chronic

lymphocytic leukemia

CD52

Millennium

Pharmaceuticals

and Genzyme

(2001)

Efalizumab

Raptiva^®

Psoriasis

CD11a

Merck Serono,

Genentech

(Roche) (2003)

Omalizumab

Xolair^®

Asthma

IgE

Genentech

(Roche),

Novartis (2003)

Bevacizumab

Avastin^®

Metastatic colorectal

cancer; non-small cell

lung cancer, metastatic

breast cancer

VEGF

Genentech

(Roche) (2004)

Natalizumab

Tysabri^®

Multiple sclerosis,

Crohn’s disease

VLA-4

Biogen Idec and

Elan (2004)

Catumaxomab

Proxinium^®

Head and neck cancer

EpCAM

Viventia (Eleven

Biotherapeutics)

(2005)

Eculizumab

Soliris^®

Paroxysmal nocturnal

hemoglobinuria

Complement

C5

Alexion

Pharmaceuticals

(2007)

Tocilizumab

RoActemra^®

Rheumatoid arthritis

IL-6 receptor

Chugai (Roche)

(2010)

Pertuzumab

Perjeta^®

Breast cancer

HER2

Roche (2012)

Obinutuzumab

Gazyvaro^®

CLL

CD20

Roche (2013)

Trastuzumab

emtansine

Kadcyla^®

Breast cancer

HER2

Roche (2013)

Alemtuzumab

Lemtrada^®

Multiple sclerosis

CD52

Sanofi(2014)

Vedolizumab

Entyvio^®

Ulcerative colitis,

Crohn’s disease

Integrin-α

4β7

Takeda Pharma

(2014)

Ocrelizumab

Ocrevus™

Multiple sclerosis

CD20

Genentech

(Roche) (2017)

406

S. K. Gupta and P. Chaudhary